Twitter Lays Off Third Of Talent Team

Cannabis companies' stocks have rallied recently on renewed optimism that the DEA may reschedule marijuana to a Schedule III substance. Last week, FDA Commissioner Robert Califf  told a House committee that there is  "no reason" for the DEA to delay the rescheduling of marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act. He also suggested medical and recreational marijuana could have separate regulations.